



**PARIS May 5, 2019: Bio-Modeling Systems is participating to Neurodegenerative Drug Development Europe Conference in Paris (May 22-23, 2019).**

***We successfully applied CADI\*™ Discovery to neurodegenerative diseases. Meet us at NDD Europe to discover our Alzheimer's and Parkinson's diseases solutions.*** (For all details and explanations download our [Short corporate Presentation](#)):

1. Our CADI\*™ treatment for Parkinson's disease is now awaiting clinical validation.
2. Our causal CADI\*™ AD model that already explains [14 key disease components](#), is unifying opposing viewpoints while clarifying much of the inconsistencies in the bibliography.
3. In its current state, our CADI\*™ AD model describes the causal and progression mechanisms of the disease, producing biomarkers promoting increased vigilance against AD in the early stages of its progression.
4. Our World's first in-vivo validated CADI™ model of Creutzfeldt-Jakob disease pathogenesis & progression mechanisms, with two Awards, reveals the role of Astrocytes and Glial cells in this context.

[May 22-23, 2019 Paris](#): BMSystems will be participating to NDD ([Neurodegenerative Drug Development](#)) Europe 2019. This is an opportunity to meet with the participating pharma industry neurology leaders (Eli Lilly, Esai, Lundbeck, Roche, GSK, Janssen, UCB, AbbVie, Sanofi, and Servier) to discuss the applications of Mechanisms-Based Medicine in neurology and present our neurology programs including our evaluation-ready [novel concepts for Alzheimer's disease](#).

We will, furthermore, be open to discussion about our new CADI™ dual therapeutic program for Metabolic Syndrome and Parkinson's disease, now completed and awaiting clinical validation.

Latest news: We are the integrative biology partner of the H2020 GEMMA (Autism & Microbiota) program that started on January 1st, 2019 ([www.gemma-project.eu](http://www.gemma-project.eu)) with 14,2 M€ E.C. funding. GEMMA has assembled a team of scientists from [EBRIS](#); [Bio-Modeling Systems](#); [Massachusetts General Hospital for Children \(teaching hospital of Harvard Medical School\)](#); [Imperial College London](#); [John Hopkins University](#); [Nutricia Research](#); [Utrecht University](#); [University of Tampere](#); [Theoreo](#); [National University of Ireland Galway](#); [Azienda Sanitaria Locale Salerno](#); [Consiglio Nazionale delle Ricerche](#); [INRA](#) and [INSERM](#).

We warmly invite you to download [our Short corporate Presentation](#).

Do not hesitate to contact us for more information or any request.

Manuel Gea CEO; VP R&D IT [manuel.gea@bmsystems.net](mailto:manuel.gea@bmsystems.net)

About Bio-Modeling Systems (BMSystems):

Bio-Modeling Systems, [the world's first Mechanisms-Based Medicine company](#), has generated 14 successes independently validated by our clients/partners of which: a world's first in neurodegenerative diseases, 1 therapeutic spin-off, 1 exclusive out-license, 4 issued patents, 10 publications ([for all details, visit our website](#)).

\*CADI: Computer Augmented Deductive Intelligence